Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Varsha Gandhi, PhD, on Ibrutinib

Jul

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Varsha Gandhi, PhD, on Ibrutinib

Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative

AACR Statement and Call to Action Concerning OMB Proposal

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease